Adjuvant therapy of negative and cognitive disorders in schizophrenia with racemate of gopantenic acid

Abstract

Nowadays efficacy of antipsychotic treatment of negative disorders in schizophrenia is often appreciated as insufficient. It causes the search for new drugs or drugs combination for increase
of tolerability and efficacy of antipsychotic.
In naturalistic study of augmentation with gopantenic acid (Pantogam Aktiv, 1200:1800 mg daily) treatment of schizophrenia patients with negative disorders there was statistically significant
reduction of total score on CGI:S (:13,7 % vs. –9,6 %, p < 0,05), PANSS (:25,3 % vs –20 %, p < 0,05) and BPRS. Dynamics of cognitive functions in patients of both group (p < 0,01), s
show greater positive effect in Pantogam Aktiv group. Pantogam active prevents or diminishes symptoms of neuroleptic depression (45,4 % HDRS total score reduction in the main group
vs 5,3 % increase in control group). Using Pantogam Aktiv in treatment regimen of negative disorders decreases extrapyramidal disorders. Everyday functioning of patients (GAF scale) in
the main group improves on 60,8 % vs 35 % in control group (р < 0,01), mental state (SF:36) improves on 73,9 % vs 49,5 % (p < 0,01), physical state improves on 46,4 % vs 34,4 %.
Conclusion. Inclusion of D, L:gopantenic acid (Pantogam Aktiv) in treatment of negative symptoms of schizophrenia increases efficacy and tolerability of combined therapy, improves quality
of life from the patient’s and doctor’s point of view.